Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Autoimmunity

  • 255 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next →
Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen
Cassian Sitaru, … , Akira Ishiko, Detlef Zillikens
Cassian Sitaru, … , Akira Ishiko, Detlef Zillikens
Published April 1, 2005
Citation Information: J Clin Invest. 2005;115(4):870-878. https://doi.org/10.1172/JCI21386.
View: Text | PDF

Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen

  • Text
  • PDF
Abstract

Epidermolysis bullosa acquisita (EBA) is a subepidermal blistering disorder associated with tissue-bound and circulating autoantibodies specific to type VII collagen, a major constituent of the dermal-epidermal junction. Previous attempts to transfer the disease by injection of patient autoantibodies into mice have been unsuccessful. To study the pathogenic relevance of antibodies specific to type VII collagen in vivo, we generated and characterized rabbit antibodies specific to a murine form of this antigen and passively transferred them into adult nude, BALB/c, and C57BL/6 mice. Immune rabbit IgG bound to the lamina densa of murine skin and immunoblotted type VII collagen. Mice injected with purified IgG specific to type VII collagen, in contrast to control mice, developed subepidermal skin blisters, reproducing the human disease at the clinical, histological, electron microscopical, and immunopathological levels. Titers of rabbit IgG in the serum of mice correlated with the extent of the disease. F(ab′)2 fragments of rabbit IgG specific to type VII collagen were not pathogenic. When injected into C5-deficient mice, antibodies specific to type VII collagen failed to induce the disease, whereas C5-sufficient mice were susceptible to blister induction. This animal model for EBA should facilitate further dissection of the pathogenesis of this disease and development of new therapeutic strategies.

Authors

Cassian Sitaru, Sidonia Mihai, Christoph Otto, Mircea T. Chiriac, Ingrid Hausser, Barbara Dotterweich, Hitoshi Saito, Christian Rose, Akira Ishiko, Detlef Zillikens

×

Synergy between a plasminogen cascade and MMP-9 in autoimmune disease
Zhi Liu, … , Robert M. Senior, Zena Werb
Zhi Liu, … , Robert M. Senior, Zena Werb
Published April 1, 2005
Citation Information: J Clin Invest. 2005;115(4):879-887. https://doi.org/10.1172/JCI23977.
View: Text | PDF

Synergy between a plasminogen cascade and MMP-9 in autoimmune disease

  • Text
  • PDF
Abstract

Extracellular proteolysis by the plasminogen/plasmin (Plg/plasmin) system and MMPs is required for tissue injury in autoimmune and inflammatory diseases. We demonstrate that a Plg cascade synergizes with MMP-9/gelatinase B in vivo during dermal-epidermal separation in an experimental model of bullous pemphigoid (BP), an autoimmune disease. BP was induced in mice by antibodies to the hemidesmosomal antigen BP180. Mice deficient in MMP-9 were resistant to experimental BP, while mice deficient in Plg and both tissue Plg activator (tPA) and urokinase Plg activator (uPA) showed delayed and less intense blister formation induced by antibodies to BP180. Plg-deficient mice reconstituted locally with Plg or the active form of MMP-9 (actMMP-9), but not the proenzyme form of MMP-9 (proMMP-9), developed BP. In contrast, proMMP-9 or actMMP-9, but not Plg, reconstituted susceptibility of MMP-9–deficient mice to the skin disease. In addition, MMP-3–deficient mice injected with pathogenic IgG developed the same degree of BP and expressed levels of actMMP-9 in the skin similar to those of WT controls. Thus, the Plg/plasmin system is epistatic to MMP-9 activation and subsequent dermal-epidermal separation in BP.

Authors

Zhi Liu, Ning Li, Luis A. Diaz, Michael Shipley, Robert M. Senior, Zena Werb

×

Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV
Yuang-Taung Juang, … , Vasileios C. Kyttaris, George C. Tsokos
Yuang-Taung Juang, … , Vasileios C. Kyttaris, George C. Tsokos
Published April 1, 2005
Citation Information: J Clin Invest. 2005;115(4):996-1005. https://doi.org/10.1172/JCI22854.
View: Text | PDF

Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) T cells express high levels of cAMP response element modulator (CREM) that binds to the IL-2 promoter and represses the transcription of the IL-2 gene. This study was designed to identify pathways that lead to increased binding of CREM to the IL-2 promoter in SLE T cells. Ca2+/calmodulin–dependent kinase IV (CaMKIV) was found to be increased in the nucleus of SLE T cells and to be involved in the overexpression of CREM and its binding to the IL-2 promoter. Treatment of normal T cells with SLE serum resulted in increased expression of CREM protein, increased binding of CREM to the IL-2 promoter, and decreased IL-2 promoter activity and IL-2 production. This process was abolished when a dominant inactive form of CaMKIV was expressed in normal T cells. The effect of SLE serum resided within the IgG fraction and was specifically attributed to anti–TCR/CD3 autoantibodies. This study identifies CaMKIV as being responsible for the increased expression of CREM and the decreased production of IL-2 in SLE T cells and demonstrates that anti–TCR/CD3 antibodies present in SLE sera can account for the increased expression of CREM and the suppression of IL-2 production.

Authors

Yuang-Taung Juang, Ying Wang, Elena E. Solomou, Yansong Li, Christian Mawrin, Klaus Tenbrock, Vasileios C. Kyttaris, George C. Tsokos

×

The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses
Yang Wang, … , Klaus Pfeffer, Yang-Xin Fu
Yang Wang, … , Klaus Pfeffer, Yang-Xin Fu
Published March 1, 2005
Citation Information: J Clin Invest. 2005;115(3):711-717. https://doi.org/10.1172/JCI22982.
View: Text | PDF

The role of herpesvirus entry mediator as a negative regulator of T cell–mediated responses

  • Text
  • PDF
Abstract

Herpesvirus entry mediator (HVEM), a TNF receptor superfamily member, has been previously described as a T cell costimulatory receptor. Surprisingly, HVEM–/– T cells showed enhanced responses to in vitro concanavalin A (ConA) stimulation when compared with WT T cells. Consistent with these findings, HVEM–/– mice exhibited increased morbidity and mortality as compared with WT mice in a model of ConA-mediated T cell–dependent autoimmune hepatitis. HVEM–/– mice produced higher levels of multiple cytokines, which were dependent on the presence of CD4+ T cells. Furthermore, HVEM–/– mice were more susceptible to MOG peptide–induced experimental autoimmune encephalopathy, and they showed increased T cell proliferation and cytokine production in response to antigen-specific challenge. Taken together, our data revealed an unexpected regulatory role of HVEM in T cell–mediated immune responses and autoimmune diseases.

Authors

Yang Wang, Sumit K. Subudhi, Robert A. Anders, James Lo, Yonglian Sun, Sarah Blink, Yugang Wang, Jing Wang, Xiaojuan Liu, Karin Mink, Daniel Degrandi, Klaus Pfeffer, Yang-Xin Fu

×

Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9
Terry K. Means, … , Douglas T. Golenbock, Andrew D. Luster
Terry K. Means, … , Douglas T. Golenbock, Andrew D. Luster
Published February 1, 2005
Citation Information: J Clin Invest. 2005;115(2):407-417. https://doi.org/10.1172/JCI23025.
View: Text | PDF

Human lupus autoantibody–DNA complexes activate DCs through cooperation of CD32 and TLR9

  • Text
  • PDF
Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by pathogenic autoantibodies against nucleoproteins and DNA. Here we show that DNA-containing immune complexes (ICs) within lupus serum (SLE-ICs), but not protein-containing ICs from other autoimmune rheumatic diseases, stimulates plasmacytoid DCs (PDCs) to produce cytokines and chemokines via a cooperative interaction between Toll-like receptor 9 (TLR9) and FcγRIIa (CD32). SLE-ICs transiently colocalized to a subcellular compartment containing CD32 and TLR9, and CD32+, but not CD32–, PDCs internalized and responded to SLE-ICs. Our findings demonstrate a novel functional interaction between Fc receptors and TLRs, defining a pathway in which CD32 delivers SLE-ICs to intracellular lysosomes containing TLR9, inducing a signaling cascade leading to PDC activation. These data demonstrate that endogenous DNA-containing autoantibody complexes found in the serum of patients with SLE activate the innate immune system and suggest a novel mechanism whereby these ICs contribute to the pathogenesis of this autoimmune disease.

Authors

Terry K. Means, Eicke Latz, Fumitaka Hayashi, Mandakolathur R. Murali, Douglas T. Golenbock, Andrew D. Luster

×

A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes
Urs Christen, … , Michael B.A. Oldstone, Matthias G. von Herrath
Urs Christen, … , Michael B.A. Oldstone, Matthias G. von Herrath
Published November 1, 2004
Citation Information: J Clin Invest. 2004;114(9):1290-1298. https://doi.org/10.1172/JCI22557.
View: Text | PDF

A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes

  • Text
  • PDF
Abstract

We document here that infection of prediabetic mice with a virus expressing an H-2Kb–restricted mimic ligand to a self epitope present on β cells accelerates the development of autoimmune diabetes. Immunization with the mimic ligand expanded autoreactive T cell populations, which was followed by their trafficking to the islets, as visualized in situ by tetramer staining. In contrast, the mimic ligand did not generate sufficient autoreactive T cells in naive mice to initiate disease. Diabetes acceleration did not occur in H-2Kb–deficient mice or in mice tolerized to the mimic ligand. Thus, arenavirus-expressed mimics of self antigens accelerate a previously established autoimmune process. Sequential heterologous viral infections might therefore act in concert to precipitate clinical autoimmune disease, even if single exposure to a viral mimic does not always cause sufficient tissue destruction.

Authors

Urs Christen, Kurt H. Edelmann, Dorian B. McGavern, Tom Wolfe, Bryan Coon, Meghann K. Teague, Stephen D. Miller, Michael B.A. Oldstone, Matthias G. von Herrath

×

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells
Hélène Bour-Jordan, … , Matthew R. Bernhard, Jeffrey A. Bluestone
Hélène Bour-Jordan, … , Matthew R. Bernhard, Jeffrey A. Bluestone
Published October 1, 2004
Citation Information: J Clin Invest. 2004;114(7):979-987. https://doi.org/10.1172/JCI20483.
View: Text | PDF

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells

  • Text
  • PDF
Abstract

The development of autoimmune diabetes in the nonobese diabetic (NOD) mouse results from a breakdown in tolerance to pancreatic islet antigens. CD28-B7 and CD40 ligand–CD40 (CD40L-CD40) costimulatory pathways affect the development of disease and are promising therapeutic targets. Indeed, it was shown previously that diabetes fails to develop in NOD–B7-2–/– and NOD-CD40L–/– mice. In this study, we examined the relative role of these 2 costimulatory pathways in the balance of autoimmunity versus regulation in NOD mice. We demonstrate that initiation but not effector function of autoreactive T cells was defective in NOD–B7-2–/– mice. Moreover, the residual proliferation of the autoreactive cells was effectively controlled by CD28-dependent CD4+CD25+ regulatory T cells (Treg’s), as depletion of Treg’s partially restored proliferation of autoreactive T cells and resulted in diabetes in an adoptive-transfer model. Similarly, disruption of the CD28-B7 pathway and subsequent Treg deletion restored autoimmunity in NOD-CD40L–/– mice. These results demonstrate that development of diabetes is dependent on a balance of pathogenic and regulatory T cells that is controlled by costimulatory signals. Thus, elimination of Treg’s results in diabetes even in the absence of costimulation, which suggests a need for alternative strategies for immunotherapeutic approaches.

Authors

Hélène Bour-Jordan, Benoît L. Salomon, Heather L. Thompson, Gregory L. Szot, Matthew R. Bernhard, Jeffrey A. Bluestone

×

Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes
Leendert A. Trouw, … , Cees van Kooten, Mohamed R. Daha
Leendert A. Trouw, … , Cees van Kooten, Mohamed R. Daha
Published September 1, 2004
Citation Information: J Clin Invest. 2004;114(5):679-688. https://doi.org/10.1172/JCI21075.
View: Text | PDF

Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes

  • Text
  • PDF
Abstract

Anti-C1q autoantibodies are present in sera of patients with several autoimmune diseases, including systemic lupus erythematosus (SLE). Strikingly, in SLE the presence of anti-C1q is associated with the occurrence of nephritis. We have generated mouse anti–mouse C1q mAb’s and used murine models to investigate whether anti-C1q autoantibodies actually contribute to renal pathology in glomerular immune complex disease. Administration of anti-C1q mAb JL-1, which recognizes the collagen-like region of C1q, resulted in glomerular deposition of C1q and anti-C1q autoantibodies and mild granulocyte influx, but no overt renal damage. However, combination of JL-1 with a subnephritogenic dose of C1q-fixing anti–glomerular basement membrane (anti-GBM) antibodies enhanced renal damage characterized by persistently increased levels of infiltrating granulocytes, major histological changes, and increased albuminuria. This was not observed when a non–C1q-fixing anti-GBM preparation was used. Experiments with different knockout mice showed that renal damage was dependent not only on glomerular C1q and complement activation but also on Fcγ receptors. In conclusion, anti-C1q autoantibodies deposit in glomeruli together with C1q but induce overt renal disease only in the context of glomerular immune complex disease. This provides an explanation why anti-C1q antibodies are especially pathogenic in patients with SLE.

Authors

Leendert A. Trouw, Tom W.L. Groeneveld, Marc A. Seelen, Jacques M.G.J. Duijs, Ingeborg M. Bajema, Frans A. Prins, Uday Kishore, David J. Salant, J. Sjef Verbeek, Cees van Kooten, Mohamed R. Daha

×

Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell–mediated spontaneous autoimmune arthritis in mice
Hiroshi Hata, … , Takashi Nakamura, Shimon Sakaguchi
Hiroshi Hata, … , Takashi Nakamura, Shimon Sakaguchi
Published August 16, 2004
Citation Information: J Clin Invest. 2004;114(4):582-588. https://doi.org/10.1172/JCI21795.
View: Text | PDF

Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell–mediated spontaneous autoimmune arthritis in mice

  • Text
  • PDF
Abstract

Cytokines play key roles in spontaneous CD4+ T cell–mediated chronic autoimmune arthritis in SKG mice, a new model of rheumatoid arthritis. Genetic deficiency in IL-6 completely suppressed the development of arthritis in SKG mice, irrespective of the persistence of circulating rheumatoid factor. Either IL-1 or TNF-α deficiency retarded the onset of arthritis and substantially reduced its incidence and severity. IL-10 deficiency, on the other hand, exacerbated disease, whereas IL-4 or IFN-γ deficiency did not alter the disease course. Synovial fluid of arthritic SKG mice contained high amounts of IL-6, TNF-α, and IL-1, in accord with active transcription of these cytokine genes in the afflicted joints. Notably, immunohistochemistry revealed that distinct subsets of synovial cells produced different cytokines in the inflamed synovium: the superficial synovial lining cells mainly produced IL-1 and TNF-α, whereas scattered subsynovial cells produced IL-6. Thus, IL-6, IL-1, TNF-α, and IL-10 play distinct roles in the development of SKG arthritis; arthritogenic CD4+ T cells are not required to skew to either Th1 or Th2; and the appearance of rheumatoid factor is independent of joint inflammation. The results also indicate that targeting not only each cytokine but also each cell population secreting distinct cytokines could be an effective treatment of rheumatoid arthritis.

Authors

Hiroshi Hata, Noriko Sakaguchi, Hiroyuki Yoshitomi, Yoichiroh Iwakura, Kenji Sekikawa, Yoshiaki Azuma, Chieko Kanai, Eiko Moriizumi, Takashi Nomura, Takashi Nakamura, Shimon Sakaguchi

×

Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease
Timothy S. Olson, … , Fabio Cominelli, Klaus Ley
Timothy S. Olson, … , Fabio Cominelli, Klaus Ley
Published August 1, 2004
Citation Information: J Clin Invest. 2004;114(3):389-398. https://doi.org/10.1172/JCI20855.
View: Text | PDF

Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease

  • Text
  • PDF
Abstract

SAMP1/YitFc mice develop discontinuous, transmural inflammatory lesions in the terminal ileum, similar to what is found in human Crohn disease. Compared with the mesenteric lymph nodes (MLNs) of AKR control mice, SAMP1/YitFc MLNs contain a 4.3-fold expansion in total B cell number and a 2.5-fold increased percentage of CD4+ T cells expressing the αEβ7 integrin. Although αEβ7+CD4+ T cells possess a regulatory phenotype (CD25+, L-selectinlo, and CD45RBlo), express IL-10, and suppress effector T cell proliferation in vitro, they cannot prevent ileitis development in SCID mice adoptively transferred with effector CD4+ T cells, although the CD4+CD25+ subset, which overlaps with the αEβ7+CD4+ subset, prevents colitis. The αEβ7+CD4+ T cells express high levels of ICOS, a costimulatory molecule that augments B cell function, suggesting their involvement in the increase in B cells, IgA+ cells, and soluble IgA found within the MLNs and ileum of SAMP1/YitFc mice. MLN B cell numbers correlate with ileitis severity in SAMP1/YitFc mice, and cotransfer of SAMP1/YitFc MLN B cells along with CD4+ T cells increases ileitis severity in SCID mice compared with transfer of CD4+ T cells alone. SAMP1/YitFc B cells prevent αEβ7+CD4+ T cells from suppressing effector T cell proliferation. We conclude that SAMP1/YitFc MLN B cells contribute to the development of SAMP1/YitFc ileitis.

Authors

Timothy S. Olson, Giorgos Bamias, Makoto Naganuma, Jesús Rivera-Nieves, Tracy L. Burcin, William Ross, Margaret A. Morris, Theresa T. Pizarro, Peter B. Ernst, Fabio Cominelli, Klaus Ley

×
  • ← Previous
  • 1
  • 2
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts